65,437 trials
Secondary Amenorrhea
Primary: Secretory Conversion of the Endometrium — 23; 28; 70; 53 participants
Hereditary Angioedema
Primary: Time to Beginning of Substantial Relief of the Defining Symptom — 2.0; 4.0 hours — p=0.048
Multiple Sclerosis
Primary: Spontaneous Abortion — 2; 0 Participants
Myelodysplastic Syndromes
Primary: Number of Participants In Best Hematological Response Categories as Determined by the Investigator Using International Working Group 2000 (IWG 2000) Criteria For…
Gastric Ulcer · Duodenal Ulcer · Rheumatoid Arthritis
Primary: Absence of Gastric and/or Duodenal Ulcer Throughout the Treatment Period — 167; 112 Participants
Psoriasis
Primary: Number of Participants Who Achieved a Physician's Global Assessment (PGA) of Clear (0) or Minimal (1) at Week 16 — 25; 14; 40 Participants
Schizophrenia
Primary: Time to Relapse or an Impending Relapse — 0; 3; 1; 14 relapses
HIV-1 Infection · HIV Infections
Primary: Plasma Area Under Curve (AUC 0-12 hr ) for Raltegravir — 12.36; 17.95; 17.12 µM*hr
Periodontitis
Primary: Overall PD Reduction — 1.25; 0.66 mm
Carcinoma, Renal Cell
Primary: Best Response - mITT (Modified Intent-to-treat) Population — 8 Participants
Hypertension
Primary: Mean Change From Baseline in Trough Sitting Systolic Blood Pressure (SiSBP) at Week 8 — -12.1; -6.8 mm Hg
Restless Legs Syndrome
Primary: Mean Change From Baseline in the International Restless Legs Syndrome (IRLS) Rating Scale Total Score at Week 12 and Week 26 — -12.1; -14.2; -13.4; -15.9 points on a…
Type 2 Diabetes Mellitus (T2DM)
Primary: Change From Baseline in A1C at Week 18 — -1.00; 0.02 Percent — p=<0.001
Ulcerative Colitis
Primary: Proportion of Participants With Clinical Remission Per Mayo Score at Week 8 — 9.2; 10.0; 18.5 Proportion of participants — p=0.031
Asthma, Exercise-Induced
Primary: Maximum Percent Fall in Forced Expiratory Volume in 1 Second (FEV1) After Exercise Challenge at 2 Hours Post-dose in Patients With Exercise-Induced Bronchoconstriction…